Louisiana Cancer Facts & Figures, Myeloma

Transcription

1 Louisiana Cancer Facts & Figures, Myeloma Louisiana Tumor Registry January 5, 6

2 Myeloma* Myeloma was the 8 th most commonly diagnosed cancer in Louisiana and the 9 th in the U.S. It was the 6 th leading cause of cancer death in Louisiana and the 5 th in the U.S. About 47 new myeloma cases are expected to be diagnosed and about 9 persons are expected to die of this cancer in Louisiana in 7. Data source: Centers for Disease Control and Prevention Data source: American Cancer Society, Cancer Facts & Figures 6 * ICD_O_3/WHO 8: , 9734.

3 Rate per, %* 6.9 Myeloma: Incidence Rates, Louisiana vs. US, Louisiana U.S..5 White Male Black Male White Female Black Female Age-adjusted to the U.S. standard population. Incidence data source:8 SEER registries. * Incidence rate of Louisiana is significantly different from that of the U.S.

4 Myeloma: Age-Specific Incidence Rates by Race and Sex, Louisiana, 9-3 Rate Per, White Male Black Male White Female Black Female Age at Diagnosis U.S. data source:8 SEER registries.

5 Rate Per, Myeloma: Age-Specific Incidence Rates by Gender, 9-3 LA Male U.S. Male LA Female U.S. Female Age at Diagnosis U.S. data source:8 SEER registries.

6 Myeloma: Age-Specific Incidence Rates by Race, 9-3 Rate Per, LA White U.S. White LA Black U.S. Black Age at Diagnosis U.S. data source:8 SEER registries.

7 Rate Per, Myeloma Incidence, by Region: Louisiana, Whites, * * * 5.9 Age-adjusted to the U.S. standard population. Data source for the U.S. was the 8 SEER registries. * Incidence rate of regions/louisiana is significantly different from that of the U.S.

8 Myeloma Incidence, by Region: Louisiana, Black, 9-3 Rate Per, * 3. Age-adjusted to the U.S. standard population. Data source for the U.S. was the 8 SEER registries. * Incidence rate of regions/louisiana is significantly different from that of the U.S.

9 Rate Per, Myeloma: Trends of Incidence Rates,, Whites, LA Male U.S. Male LA Female U.S. Female Year of Diagnosis Age-adjusted to the U.S. standard population. U.S. data source: 8 SEER registries.

10 Myeloma: Trends of Incidence Rates,, Blacks, -3 Rate Per, LA Male U.S. Male LA Female U.S. Female Year of Diagnosis Age-adjusted to the U.S. standard population. U.S. data source: 8 SEER registries.

11 Myeloma: Mortality Rates, Louisiana vs. US, 9-3 Louisiana U.S Rate Per, White Male White Female Black Male Black Female Age-adjusted to the U.S. standard population. Data source: National Center of Health Statistics (NCHS).

12 Myeloma: Trends of Mortality Rates,, Whites,988-3 Rate per, LA Male U.S. Male LA Female U.S. Female Year of Death Adjusted to the U.S. standard population. Data source: National Center of Health Statistics (NCHS).

13 Myeloma: Trends of Mortality Rates,, Blacks,988-3 Rate Per, LA Male LA Female U.S. Male U.S. Female Year of Death Age-adjusted to the U.S. standard population. Data source: National Center of Health Statistics (NCHS).

14 Myeloma: Trends of Incidence and Mortality Rates, by Race, Louisiana, Rate per, White Incidence (APC:.4) Black Incidence (APC:.7*) White Mortality (APC :-.*) Black Mortality (APC: -.6) Year of Diagnosis/Death APCs were calculated using weighted least squares method.

15 Rate Per, Myeloma: Trends of Incidence and Mortality Rates, by Gender, Louisiana, Male Mortality (APC: -.9*) Female Mortality (APC: -.*) Male Incidence (APC:.5*) Female Incidence (APC:.5*) Year of Diagnsis/Death *APCs were calculated using weighted least squares method

16 Myeloma: Louisiana 5-Year Relative Survival by Stage, All Races, Both Sexes, 6-5-Year Relative survival rate(%) 7% 6% 5% 4% 3% % % % Percent of Cases by Stage Distant 94% Localized 6% Localized Distant The stage distribution is based on Derived Summary Stage.

17 Myeloma: Louisiana 5-Year Relative Survival by Stage, White Males, 6-6% 5% 4% 3% % % % 5-Year Relative survival rate(%)7% Distant 94% Percent of Cases by Stage Localized 6% Localized Distant The stage distribution is based on Derived Summary Stage.

18 5-Year Relative survival rate(%) Myeloma: Louisiana 5-Year Relative Survival by Stage, Black Males, 6-7% 6% 5% 4% 3% % % % 57.7 Localized 43.4 Distant Percent of Cases by Stage Distant 94% Localized 6% The stage distribution is based on Derived Summary Stage.

19 5-Year Relative survival rate(%) Myeloma: Louisiana 5-Year Relative Survival by Stage, White Females, 6-54% 53% 5% 5% 5% 49% 48% 47% 5.9 Localized 49. Distant Distant 94% The stage distribution is based on Derived Summary Stage. Percent of Cases by Stages Localized 6%

20 Myeloma: Louisiana 5-Year Relative Survival by Stage, Black Females, 6-5-Year Relative survival rate(%) 8% 7% 6% 5% 4% 3% % % % Localized Distant Distant 95% Percent of Cases by Stages Localized 5% The stage distribution is based on Derived Summary Stage.

21 Data Sources Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Databases, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 6, based on the November 5 submission. For Incidence: Incidence - SEER 8 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 5 Sub (-3) <Katrina/Rita Population Adjustment> SEER*DMS - LTR 988-3, June 7, 6 For Mortality: mortality all COD, aggregated with States, Total U.S. (969-3) <Katrina/Rita Population Adjustment> For Survival: Incidence - SEER 8 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 5 Sub (973-3 varying)

22 Acknowledgements Hospital cancer registries ( Louisiana Cancer Registrars Association ( Physicians and staff members in: Medical records offices Pathology laboratories Physician offices and clinics Hospice programs and nursing homes Regional and central offices of the Louisiana Tumor Registry ( School of Public Health, LSU Health Sciences Center New Orleans Louisiana Cancer and Lung Trust Fund Board Coroners offices

23 Sources of LTR Funding National Cancer Institute, SEER Program National Program of Cancer Registries, CDC Louisiana Health Care Services Division

24 Editors Shuang Yang, MPH Meichin Hsieh, PhD, MSPH, CTR Lauren Maniscalco, MPH Xiaocheng Wu, MD, MPH, CTR Contributors Xiangrong Li, MD, MSPH Brent Mumphrey, BS Tina Lefante, MPH Lisa Pareti, BS, RHIT, CTR Yong Yi, PhD, MS

25 Questions? Contact: or